Search Details

Word: amerisourcebergen (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

Nearly 4 billion prescriptions are filled at 54,000 pharmacies across the U.S. each year. But getting medications from their makers into the hands of their takers is largely the job of a wholesaling oligopoly. Cardinal and its principal rivals--San Francisco--based McKesson Corp. and AmerisourceBergen, based in Valley Forge, Pa.--control 90% of the market, acting as middlemen to pool purchasing power and to guarantee 24/7 access to millions of medications...

Author: /time Magazine | Title: Prescription for a Turnaround | 2/15/2010 | See Source »

...expected to replace 80% of the revenue from brand-name drugs by 2015. "Generics mean slow top-line growth but are ultimately much more profitable for wholesalers," says Richard Close, an analyst for Jefferies & Co. "By focusing on the big chains, Cardinal had basically ceded generics to McKesson and AmerisourceBergen...

Author: /time Magazine | Title: Prescription for a Turnaround | 2/15/2010 | See Source »

...fast if, as Barrett says, it wants to catch up with rivals on delivering specialty drugs. Netting $134 billion globally in 2008, these therapies for treating chronic diseases--about half of which are oncology drugs--represent one of the fastest-growing segments of the health care market. AmerisourceBergen's revenue in the sector topped $16 billion last fiscal year. "If Cardinal is going to play, they have to move now," says Sanford C. Bernstein & Co. analyst Helene Wolk, who is bearish on Cardinal. "And they're going to have to buy, not build, to get to scale as quickly...

Author: /time Magazine | Title: Prescription for a Turnaround | 2/15/2010 | See Source »

...Cardinal announced that its second-quarter revenue increased 3%, to $25 billion, supplemented by a 38% increase in profit on the medical-supply side. But perhaps even better news came when AmerisourceBergen and McKesson unveiled their earnings a few days earlier. Whereas a year ago, one of the two might have boasted about winning some of Cardinal's business, this time around, says Gill, "the same competitor is saying the exact opposite: 'We think all of our competitors are in good places, and given the stickiness, we don't expect any big accounts to change hands.'" In other words, Cardinal...

Author: /time Magazine | Title: Prescription for a Turnaround | 2/15/2010 | See Source »

...AmerisourceBergen...

Author: /time Magazine | Title: Where the Fortune 50 CEOs Went to College | 8/15/2006 | See Source »

| 1 |